Friday, May 26, 2023
HeartBeam announced that it has received a notice of allowance from The United States Patent and Trademark Office for a key patent relating to the initial AI capability in the form of an expert system for its HeartBeam AIMIGoTM System. The patent is entitled, “Hand Held Device for Automatic Cardiac Risk and Diagnostic Assessment.”
The newly allowed patent describes a system that combines the recorded cardiac signals from the HeartBeam AIMIGo VECG device with the patient’s symptoms and cardiac risk factors to calculate a cardiac risk score, providing simplified diagnostic information and actionable instructions to the patient. It aims to replicate the decision-making process a physician uses when assessing a patient with cardiac symptoms but performed remotely in an automated manner.
This patent advances the efforts to establish a dominant intellectual property position in the ambulatory VECG field. Combining artificial intelligence with the most advanced ambulatory ECG equipment available can provide unprecedented diagnostic capabilities for patients with acute heart disease, ultimately leading to better care and saving lives.
